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ABSTRACT 101 
It is debated if acromegalic patients have an increased risk to develop malignancies. 102 
The aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of 103 
cancer in acromegaly on a large series of acromegalic patients managed in the somatostatin analogs era. 104 
It was evaluated the incidence of cancer in an Italian nationwide multicenter cohort study of 1512 105 
acromegalic patients, 624 men and 888 women, mean age at diagnosis 45 +/- 13 years, followed–up for a 106 
mean of 10 years (12573 person-years) in respect to the general Italian population. 107 
Cancer was diagnosed at 124 patients, 72 women and 52 men. The SIRs for all cancers was significantly 108 
increased compared to the general Italian population (expected: 88, SIR 1.41; 95%CI, 1.18-1.68, p<0.001). 109 
In the whole series, we found a significantly increased incidence of colorectal cancer (SIR 1.67; 95% 110 
CI,1.07-2.58, p=0.022), kidney cancer (SIR 2.87; 95% CI 1.55-5.34, p<0.001) and thyroid cancer (SIR 3.99; 111 
95% CI, 2.32-6.87, p<0.001). The exclusion of 11 cancers occurring before diagnosis of acromegaly (all in 112 
women) did not change remarkably the study outcome. In multivariate analysis, the factors significantly 113 
associated with an increased risk of malignancy were age and family history of cancer, with a non-significant 114 
trend for the estimated duration of acromegaly before diagnosis. 115 
In conclusion we found evidence that acromegaly in Italy is associated with a moderate increase in cancer 116 
risk. 117 
118 
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INTRODUCTION 119 
 120 
Acromegaly is an uncommon disease sustained by hypersecretion of GH and IGF-I and is associated with 121 
remarkable complications that may reduce life expectancy of these patients (Melmed 2009, Katznelson et al. 122 
2014). However, the effective control of GH and IGF-I excess is able to reduce considerably the burden of 123 
disease. Recent population-based studies have showed that acromegalic patients have lower standard 124 
mortality ratios than previously reported (Sherlock et al. 2010), reflecting improved treatment modalities that 125 
became available in recent years, such as somatostatin-receptor ligands  (SRL) and pegvisomant (Bogazzi et 126 
al. 2013, Biermasz 2014, Mercado et al. 2014) The impact of acromegaly on life expectancy comes mainly 127 
through cardiovascular and cerebrovascular events, since diabetes mellitus and hypertension are frequent 128 
complications of GH and IGF-I excess (Melmed 2001) Recently, we did a large-scale epidemiological 129 
analysis on 1512 acromegalic Italian patients and found that vascular disease and cancer were the main 130 
causes of death. Mortality was higher in patients with persistently active disease, and IGF-I levels at 131 
diagnosis, GH at the last follow-up, cancer, and pituitary radiotherapy were independent predictors of 132 
mortality (Arosio et al. 2012). 133 
That acromegaly may cause cancer, and that mortality due to cancer contributes to shorten survival of 134 
patients with acromegaly, remains an unsolved issue (Melmed 2001, Loeper & Ezzat 2008, Boguszewski & 135 
Ayuk 2016). A wealth of preclinical data supports the view that the GH-IGF system plays an important role 136 
in cancer development and progression (Loeper & Ezzat 2008, Pollak 2008, Weroha & Haluska 2012, 137 
Brahmkhatri et al. 2015). Moreover, in human studies there is convincing evidence that circulating IGF-I 138 
concentrations at the higher limit of the normal range are linked with an increased risk of several types of 139 
cancers, although the excess risk seems moderate (Renehan et al. 2004, Clayton et al. 2011). Despite a sound 140 
rationale, studies that addressed the association between acromegaly and cancer produced controversial 141 
results, partly due to the different methodological approaches used (case-control and population-based 142 
design) (Loeper & Ezzat 2008, Ayuk & Boguszewski 2016). Moreover, it is plainly evident that most studies 143 
did not have the statistical power to demonstrate a moderate excess risk of cancer, as expected from the 144 
outcome of studies in the general population and case-control studies on acromegaly (Figure 1). 145 
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A recent meta-analysis of case-control studies employing colonoscopy showed that acromegaly is associated 146 
with an increased risk of colon neoplasms, both colon adenomas, a premalignant condition that may lead to 147 
overt cancer, and colon cancers.  Results were consistent among the different studies with no significant 148 
heterogeneity and showed an overall excess risk of about two times (Rokkas et al. 2008). Another meta-149 
analysis of case-control studies focusing on thyroid cancer showed an increased risk of both nodular thyroid 150 
disease and thyroid cancer in acromegaly, and again results were quite homogeneous across studies, although 151 
with less precise estimate due to the low number of events (Wolinski et al. 2014).  152 
Population-based studies addressing cancer incidence in acromegaly produced controversial findings that 153 
may be likely explained by difference in methodology and variable sample size (Table 1). Also population-154 
based studies addressing whether cancer mortality may contribute to overall mortality of acromegaly came to 155 
mixed conclusions, with some studies showing an association while others did not (Table 2). However, it has 156 
been already argued that studies focusing on mortality are less helpful in answering the question whether 157 
acromegaly is associated with cancer because the prevalent cardiovascular mortality may have obscured 158 
cancer mortality. In the reported series, the median age at death was less than 60 years, thus most patients 159 
died before they could develop clinically evident cancer (Loeper & Ezzat 2008, Boguszewski & Ayuk 2016). 160 
The aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of 161 
cancer in acromegaly in a nationwide multicenter cohort study in Italy on a large series of acromegalic 162 
patients who have been treated in the SRL era.  163 
 164 
 165 
MATERIALS AND METHODS 166 
Subjects 167 
We have evaluated the prevalence of neoplasia from an Italian series of 1512 patients who were proactively 168 
followed in 24 tertiary referral centers in Italy. Patient characteristics are given in Table 3. Inclusion criteria 169 
were age at diagnosis >18 years and diagnosis of acromegaly made between 1 January 1980 and 31 170 
December 2002 according to standard biochemical criteria at the time of enrollment, with at least 1-year 171 
follow-up after diagnosis. The mean follow-up time from diagnosis to the end of the study was 120 months 172 
(median: 90 months; interquartile range [IQR]: 42–170 months). Follow-up was closed at the end of 2012. 173 
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Data were collected retrospectively by local investigators in a computerized dataform developed using 174 
Access 2000 software (Microsoft Corporation 1999) and approved by all participants. All patients gave their 175 
informed consent to the collection of data according to the local ethic committee indications. Briefly, we 176 
collected for each patients: demographics, estimated date of appearance of typical acromegalic signs, GH 177 
and IGF-I levels at diagnosis and last follow-up, novel diagnosis of malignancies during follow-up, data on 178 
family history of cancer, smoking, drinking, participation in oncology screening programs. For further details 179 
on data capture and assessment see Arosio et al. (Arosio et al. 2012).  180 
 181 
Statistical analysis 182 
Cancer registrations were coded using the International Classification of Diseases ICD-9, and data were 183 
compared to the general Italian population using the cancer registry AIRTUM (Associazione Italiana Registri 184 
Tumori, www.registri-tumori.it). The expected number of cancers was calculated by multiplying the number 185 
of person-years by the appropriate national, gender-, age-, calendar year-, and site-specific cancer incidence 186 
rate for each five-year age group and calendar year of observation. Risks of cancer were estimated by 187 
computing the SIRs, defined as the observed to expected number of cancers for all acromegaly patients 188 
combined, and by gender, age, and years of follow-up. The 95% confidence intervals (CI) were computed 189 
assuming that the observed number follows a Poisson distribution (Liddell 1984). 190 
Descriptive statistics were worked out. Continuous data were presented as medians and interquartile ranges, 191 
or means and standard deviations. Discrete data are given as counts and percentages. Chi-square test was 192 
performed to compare categorical data between groups and the Mann-Whitney U test was used to compare 193 
continuous data. Levels of significance were set at p<0.05. 194 
The individual effect of patient and clinical variables on the risk of cancer was evaluated by a logistic 195 
regression model and a univariate estimate of the Odds Ratios (OR) were presented along with their 95% 196 
confidence intervals (CI). A multivariable model was then considered. Variables were entered into the model 197 
following a variable selection strategy, which was based on clinical judgement and statistical selection 198 
procedures. Model fit was considered as significantly improved on the basis of the Akaike Information 199 
Criterion (AIC) applied backwards for each model (i.e. starting from a model with all relevant variables, 200 
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eliminating those that were not significant), at a significance level of 0.05. Interactions among variables were 201 
assessed by the Wald’s test.  202 
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 203 
RESULTS 204 
 205 
Cancer incidence 206 
We found 124 patients with diagnosis of cancer in our study cohort of 1512 acromegalic followed-up for a 207 
mean period of 10 years (12573 person-years). Fourteen patients had multiple cancers. Eleven subject 208 
registrations occurred before the date of diagnosis of acromegaly (8 breast, 2 colorectal, 1 uterus cancers) but 209 
were included in the analysis, since diagnosis of cancer preceded that of acromegaly of less than 5 years, 210 
which is within the time lag occurring between onset and clinical diagnosis of acromegaly in our cohort 211 
(Arosio et al. 2012). Raw data of observed malignancies are given in supplemental table 1. In a separate 212 
analysis, we restricted SIR calculation to the malignancies observed only after the clinical diagnosis of 213 
acromegaly. 214 
Overall, SIR for all cancers was increased compared to the general Italian population (SIR 1.41; 95%CI, 215 
1.18-1.68, p<0.001). In the whole series, we found a significantly increased incidence of colorectal cancer 216 
(SIR 1.67; 95% CI, 1.07-2.58, p=0.022), kidney cancer (SIR 2.87; 95% CI 1.55-5.34, p<0.001) and thyroid 217 
cancer (SIR 3.99; 95% CI, 2.32-6.87, p<0.001). We assessed the SIRs of different cancer types in the female 218 
and male gender, respectively (Table 4). In female patients, incidence of all malignancies was increased (SIR 219 
1.51; 95% CI, 1.20-1.91, p<0.001), as it was incidence of thyroid cancer, colorectal cancer, and breast 220 
cancer. In male patients, incidence of all malignancies was increased (SIR 1.29; 95% CI, 1.0-1.7, p=0.06), as 221 
it was incidence of thyroid cancer, kidney cancer, and colorectal cancer.  222 
The analysis of the malignancies observed only after the clinical diagnosis of acromegaly confirmed an 223 
increased SIR for all cancer in the overall population (SIR 1.28; 95%CI, 1.07-1.55, p=0.007). All the 224 
prevalent malignancies were observed in female patients; however, the incidence of all malignancies was 225 
still increased (SIR 1.28; 95%CI, 1.00-1.65, p<0.05) while the incidence of breast cancer (SIR 0.83; 95% CI, 226 
0.50-1.41, p=NS) and colorectal cancer (SIR 1.55; 95% CI, 0.84-2.89, p=NS) were not different from the 227 
general female population. 228 
A comparable number of patients with or without cancer were submitted to proactive oncologic screening as 229 
part of their management (65% in patients with cancer vs. 60% in patients without cancer).  230 
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Predictive factors of cancer were analyzed in univariate analysis (age, gender, duration of acromegaly before 231 
diagnosis, presence of diabetes, active disease at last follow-up, GH/IGF-I at baseline and last follow-up, 232 
pituitary radiotherapy, family history of cancer). Factors significantly associated with an increased risk of 233 
cancer were age, family history of cancer, disease duration before diagnosis, presence of diabetes and 234 
previous pituitary radiotherapy. Pertinently, we observed only 3 cases of brain cancer. In multivariable 235 
analysis, factors significantly associated with an increased risk of cancer were age and family history of 236 
cancer, while there was a non-significant trend for duration of acromegaly (Table 5). 237 
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 238 
DISCUSSION 239 
 240 
Whether acromegaly is associated with increased risk of cancer remains an endless debate. In general, case-241 
control studies focusing on a specific tumor type produced more homogeneous figures, as demonstrated by a 242 
meta-analysis of colonoscopy-based studies (Rokkas et al. 2008). Since case-control studies may lead to 243 
overestimation of risk due to ascertainment bias and problems related to matching with specific patient 244 
groups, the “well-worried” bias, it has been suggested that population-based studies are more appropriate for 245 
assessing cancer risk (Renehan & Brennan 2008).  246 
However, population-based studies produced discrepant data for a number of reasons. First, due to the rarity 247 
of acromegaly only nationwide surveys may have adequate statistical power. Second, coverage and accuracy 248 
of national cancer registries, as well as duration and completeness of follow-up, are keys for an adequate 249 
comparison with the general population. Third, the retrospective nature of these studies is an obvious 250 
limitation, particularly when considering that some studies date back to the sixties (Wright et al. 1970, 251 
Alexander et al. 1980), when treatment of acromegaly was far less effective. As a consequence, patients with 252 
uncontrolled acromegaly may have died before entering the age when cancer usually occurs; thus, 253 
competitive cardiovascular morbidity may have hindered cancer incidence and, particularly, cancer mortality 254 
(Loeper & Ezzat 2008, Boguszewski & Ayuk 2016). 255 
The aim of the present study was to evaluate the incidence of cancer in a series of 1512 acromegalic patients 256 
followed up for 10 years at 24 tertiary referral centers in Italy. Most patients were treated after the 257 
introduction of SRL in clinical practice, thus representing a modern series. We found that the overall 258 
incidence of cancer was increased compared to the general population with a SIR of 1.41 (95%CI, 1.18-259 
1.68). The excess risk is only moderate and this may explain why less powered studies produced 260 
controversial findings. Since acromegaly is usually recognized many years after its biological onset, we 261 
included in the analysis the malignancies diagnosed within a period of 5 years prior to the clinical diagnosis 262 
of acromegaly, to account for the long period of exposure to excess GH and IGF-I preceding the diagnosis. 263 
Even if malignancies detected during this time span are considered formally as prevalent, they occur under 264 
the influence of hormone excess that is present albeit undiagnosed. Pertinently, a recent survey in Denmark 265 
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identified increased morbidity over the 3 years preceding diagnosis of acromegaly (Dal et al., 2016). 266 
However, we also did a separate analysis including only the malignancies diagnosed after the clinical 267 
diagnosis of acromegaly to provide a more conservative estimate of the risk. The results of this analysis 268 
overall confirmed an excess cancer risk with the exception of breast cancer. 269 
Only three studies in the literature have a size comparable to the present one, but only two were nationwide 270 
surveys. Ron et al. (Ron et al. 1991) analyzed a cohort of 1041 male inpatients with acromegaly in the US 271 
and found an increased incidence compared to non-acromegalic hospitalized patients, who served as controls 272 
(SIR, 1.6; 95% CI, 1.3-1.9). This increased risk was mainly attributable to gastrointestinal cancers, in 273 
particular colon cancer. However, the study may be criticized for the inclusion of only male patients 274 
admitted to hospital and for not having used tumor incidence rates of the general population as reference 275 
(Loeper & Ezzat 2008). Orme et al. (Orme et al. 1998) made a large epidemiological study in the UK, 276 
analyzing a cohort of 1239 subjects with acromegaly, and found that the risk for all malignancies was 277 
reduced compared to the general population (SIR, 0.76; 95% CI, 0.60-0.95), although there was a non-278 
significant increase in the incidence of colon cancer (SIR, 1.68; P=0.06). However, they excluded 279 
approximately 17% of cancer registrations that occurred before the diagnosis of acromegaly. Since the 280 
diagnosis of acromegaly is usually made years after its biological onset, excluding such cases may cause an 281 
underestimation of the phenomenon (Loeper & Ezzat 2008, Boguszewski & Ayuk 2016). Baris et al. (Baris 282 
et al. 2002) made an epidemiological study in Sweden and Denmark, analyzing a cohort of 1634 patients, 283 
and found an increased risk for all malignancies (SIR, 1.5; 95% CI, 1.3-1.8), in particular of the digestive 284 
tract. 285 
More recently, three smaller studies have been published that provided controversial results. Kauppinen-286 
Makelin et al. (Kauppinen-Makelin et al. 2005), in a nation-wide survey in Finland, analyzed 334 patients 287 
and found an increased cancer incidence (SIR, 1.5; 95% CI, 1.1-1.9). Due to the low number of events, it 288 
was impossible to make stratification per cancer type, but colon and thyroid cancer were the most frequently 289 
observed. Petroff et al. (Petroff et al. 2015) analyzed 446 patients from the German Acromegaly Registry 290 
and found that cancer incidence was non-significantly lower than the general population (SIR, 0.75; 95% CI, 291 
0.55-1.00). They found a two times higher incidence of thyroid cancer in acromegalic patients that was not 292 
significant due to the low number of events. However, the study has limits in representing only a sample of 293 
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the German Acromegaly Registry and in the methodology used to ascertain cancer registration, which was 294 
not always based on referring to medical records but included also phone interview. Moreover, 16% of 295 
patients were lost to follow-up. Cheng et al. (Cheng et al. 2015) reported on 408 acromegalic patients 296 
followed at 3 referral centers in Canada and found that cancer incidence was higher than in the general 297 
population (OR, 2.87; 95% CI, 1.57-5.25). In this cohort, diabetes was associated to the risk of malignancy. 298 
The present study has strengths in the large population sample and long follow-up with all cancer 299 
registrations confirmed by the physicians who proactively managed the patients. Our study cohort was 300 
collected in many referral centers; thus it is representative of the acromegalic population in Italy. It is also 301 
representative of a cohort treated in a modern way as demonstrated by the overall mortality data (Arosio et 302 
al. 2012) in a range comparable to those observed in more recent studies (Katznelson et al. 2014, Sherlock et 303 
al. 2010, Mercado et al. 2014). Our findings on cancer incidence are in close agreement with the nationwide 304 
survey in Finland (Kauppinen-Makelin et al. 2005) that was done in the same time period (SIR of the present 305 
study, 1.41; SIR of the Finnish study, 1.5). The outcome of the German study (Petroff et al. 2015), which is 306 
also a contemporary series, is at variance but the above-mentioned differences in study methodology may 307 
explain the discrepancy.  308 
Due to our large sample size, we were able to consider separately cancer incidence between sexes and make 309 
a meaningful stratification of different cancer types. Risk of cancer was higher in women (SIR 1.51; 95% CI, 310 
1.20-1.91) than in men (SIR 1.29; 95% CI, 1.0-1.7), and this may be attributable to the fact that women were 311 
older in our series. Cancers found to be more consistently increased were thyroid cancer, kidney cancer and 312 
colorectal cancer. These findings are consistent with abundant evidence linking the IGF system with 313 
development and progression of all these cancers (Loeper & Ezzat 2008, Pollak 2008, Weroha & Haluska 314 
2012, Brahmkhatri et al. 2015, Renehan et al. 2004, Clayton et al. 2011, Giovannucci et al. 2000, Pekic & 315 
Popovic 2013).  316 
The increased risk of colon neoplasia in acromegaly is the most widely agreed; thus, the Endocrine Society 317 
Guidelines suggested incorporating colonoscopy at diagnosis in the management of acromegaly-related 318 
comorbidities (Katznelson et al. 2014). Higher risk of breast cancer has been reported in an old study 319 
(Nabarro 1987), while recent studies found only non-significant increase in risk (Baris et al. 2002, 320 
Kauppinen-Makelin et al. 2005, Petroff et al. 2015). However, assessing the prevalence in acromegaly of 321 
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breast cancer is particularly challenging since it may be looked at only in women, thus substantially halving 322 
the sample size. In addition, IGF-I excess could have different effects depending on the menopausal state, 323 
and on the levels of other sex and growth hormones, further increasing complexity (Renehan et al. 2004, 324 
Tworoger et al. 2011).  In recent reports, there is increasing evidence that thyroid cancer is more frequent in 325 
patients with acromegaly than in control groups (Wolinski et al. 2014). A recent cross-sectional prospective 326 
study in Spain found that either benign nodular thyroid disease or thyroid cancer were more frequent in 123 327 
patients with acromegaly than in 50 matched controls applying highly sensitive ultrasound methodology and 328 
standardized use of FNA cytology (Reverter et al. 2014). Conversely, the association between acromegaly 329 
and kidney cancer has been less frequently reported (Cheung & Boyages 1997, Baris et al. 2002, Kauppinen-330 
Makelin et al. 2005). Interestingly, expression of the IGF-I receptor has been associated with poor survival in 331 
patients with early-stage renal cancer (Parker et al. 2004). 332 
The present study is the first to provide a multivariate analysis aiming at identifying predictors of cancer in 333 
acromegaly. We found that age and family history of cancer were significant independent factors associated 334 
to cancer risk, and these findings are biologically plausible. Moreover, a non-significant trend between 335 
cancer risk and delay in acromegaly diagnosis was apparent, but it is known that the estimate of duration of 336 
acromegaly is admittedly imprecise and operator dependent. We did not find evidence of an association 337 
between values of GH and IGF-I, or both, and cancer risk. Orme et al. (Orme et al. 1998) found a higher 338 
cancer-related mortality in patients with elevated post-treatment GH but no clear link between GH and IGF-I 339 
levels and cancer incidence in acromegaly has been definitively proven. This does not discredit the view that 340 
GH and IGF-I are implicated in cancer development in acromegaly. It has to be pointed out that the 341 
hormonal evaluation at diagnosis or at the last follow-up may give only a poor estimate of patient’s exposure 342 
to GH and IGF-I in the course of a chronic disease such as acromegaly. Moreover, other factors may play 343 
important roles in determining the risk of neoplasia in acromegaly, such as insulin, insulin resistance, IGF-344 
BP1 and BP3, obesity, body composition and leptin levels (Melmed 2001, Boguszewski & Ayuk 2016, 345 
Giovannucci et al. 2000, Pekic & Popovic 2013, Tworoger et al. 2011). In this line, it is interesting the 346 
finding of Cheng et al. (Cheng et al. 2015) that acromegalic patients with diabetes had more malignant 347 
tumors than non-diabetic patients. In our cohort, diabetes was associated with cancer risk only in univariate 348 
analysis.  The alternative hypothesis that cancer risk in acromegaly is due to common underlining genetic 349 
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factors should be also considered (Loeper & Ezzat 2008, Boguszewski & Ayuk 2016, Renehan & Brennan 350 
2008).  351 
Limitations of our study are its retrospective nature, as for previous epidemiological studies, the consequent 352 
lack of data on the cumulative GH exposure, that has been recently suggested as a very important 353 
determinant of morbidity and mortality (Varadhan et al. 2016), and the fact that patients have been submitted 354 
in many centers to proactive oncologic screening, since previous studies conducted in Italy have suggested 355 
an association between acromegaly and colon neoplasia (Terzolo et al. 2005) or thyroid cancer (Gasperi et 356 
al. 2002, Tita et al. 2005). However, the rate of patients who underwent cancer screening was alike between 357 
patients with and without cancer; thus, it is unlikely that our findings are explained by an ascertainment bias.  358 
In conclusion, we found evidence that acromegaly is associated with a moderate increase in cancer risk in a 359 
nation-wide survey in Italy.  360 
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FIGURE LEGENDS 1 
Figure 1 – Sample size of the population-based studies on acromegaly and cancer. 2 
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Table 1 – Cancer incidence data in studies with more than 200 patients. 
*Hospitalized patients 
NA=Not Available 
 
Author, year 
Study 
Period 
Patients 
(n°) 
Follow-up 
(years or 
person 
years) 
Age at 
diagnosis 
CANCER 
n°, (%) 
SIR 
95% CI 
P value 
Ron, 1991 1969-1985 1041* 8619 NA 89 (8.5) 1.6 
1.3-1.9 
NA 
Orme, 1998 1958-1995 1239 16778 NA 79 (6.4) 0.76 
0.60-0.95 
1 
Popovic, 1998 1992-1998 220 4.5 49.5 23 (10.5) 3.39 
2.12-5.12 
<0.01 
Baris, 2002 1965-1993 1634* 14724 50.4 177 (10.8) 1.5 
1.3-1.8 
NA 
Kauppien-
Makelin, 2010 
1980-2006 333 10.7 47.5 48 (14.4) 1.5 
1.1-1.9 
NA 
Petroff, 2015 NA 374 6656 45.7 44 (11.8) 0.75 
0.55-1.00 
0.051 
Cheng, 2015 NA 408 10.2 43.2 55 (13.4) 2.87 
1.57-5.25 
NA 
Dal, 2016 1991-2010 405 10.6 48.7 NA 1.4   
0.9-2.2 
NA 
Maione, 2017 1977-2012 999 6728 43 men 
48.5 women 
94 (10.1%) 1.34  
(0.94–1.87) 
men 
1.24             
(0.77–1.73) 
women 
NA 
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Table 2 – Cancer mortality data in studies with more than 150 patients 
 
Author, year N. Follow-up 
Duration 
(years or 
person/years) 
Age at 
death 
Overall 
SMR 
Cancer-related 
SMR 
(95% CI) 
P 
value 
Nabarro 1987 256 20 NA 1.26 0.96 
(NA) 
NA 
Bengtsson 1988 166 30 NA NA Overall: 2.68  
Female: 3.3 
(NA) 
<0.01 
Rajasoorya 
1994 
151 12 57 NA 1 
(NA) 
NA 
Orme 1998 1362 NA NA 1.6 1.16 
(0.92–1.44) 
0.1 
Ayuk 2004 419 13 NA 1.26 0.91 
(0.59-1.39) 
0.65 
Holdaway 2004 208 13 ± 9 62 ± 2 
 
1.87 0.92 
(NA) 
NA 
Dal, 2016 405 10.6 NA 1.3 1.1  
(0.7-1.9) 
NA 
 
NA=Not Available, SMR=Standard Mortality Ratio, CI=Confidence Interval 
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Table 3 – Characteristics of the study population 
 
 
 
Sex  
Overall 
 
 
P  
value  Male Female 
Patient number 624 888 1512  
Age, yrs  
(median [IQR]) 
42.3 
[33.0, 51.7] 
47.2 
[37.1, 55.2] 
46.0 
[35.3, 54.0] 
<0.001 
Disease duration, yrs  
(median [IQR]) 
5.0 
[2.0, 9.0] 
4.5 
[2.0, 8.0] 
5.0 
[3.0, 8.0] 
NS 
IGF-I at diagnosis, SDS 
(median [IQR]) 
8.8 [6.1, 12.5 ] 8.3 [5.7, 12.0] 8.5 [5.8, 12.3] NS 
IGF-I at FU, SDS 
(median [IQR]) 
1.95 
[0.33, 4.39] 
1.11 
[0.04, 2.80] 
1.34 
[0.11, 3.50] 
<0.001 
GH at diagnosis, ng/mL 
(median [IQR]) 
20.0 
[11.0, 40.0] 
18.9 
[9.25, 35.0] 
20.0 
[10.0, 36.0] 
NS 
GH at FU, ng/mL  
(median [IQR]) 
2.0 [1.0, 3.7] 2.0 [1.0, 3.8] 2.0[1.0, 3.8] NS 
Disease remission,  n. (%) 360 (62.1) 572 (67.5) 932 (65.3) 0.038 
Cancer familiarity, n. (%) 136 (29.9) 216 (33.9) 352 (32.2) NS 
Diabetes, n. (%) 106 (17.0) 139 (15.6) 245 (16.2) NS 
Radiotherapy, n. (%) 103 (16.5) 166 (18.7) 269 (17.8) NS 
Cancer, n. (%) 52 (8.3%) 72 (8.1%) 124 (8.2%) NS 
 
IQR=Interquartile range, SDS=Standard Deviation Score, NS=Not Significant 
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Table 4 – Cancer incidence data broken down by gender 
 
Cancer type Observed Expected SIR 95% CI p-value 
Female      
All malignancies 72 47.6 1.51 1.2-1.91 <0.001 
Breast cancer 22 16.8 1.31 0.86-1.99 0.21 
Colorectal cancer 12 6.4 1.86 1.06-3.28 0.03 
Thyroid cancer 8 2.5 3.22 1.61-6.44 0.01 
Male      
All malignancies 52 40.2 1.29 1.0-1.7 0.06 
Colorectal cancer 8 5.6 1.44 0.72-2.88 0.31 
Kidney cancer 7 1.9 3.73 1.78-7.83 <0.001 
Thyroid cancer 5 0.8 6.51 2.71-15.65 <0.001 
Overall      
Colorectal cancer 20 12 1.67 1.07-2.58 0.022 
Kidney cancer 10 3.5 2.87 1.55-5.34 <0.001 
Thyroid cancer 13 3.3 3.99 2.32-6.87 <0.001 
 
SIR=Standard Incidence Ratio, CI=Confidence Interval 
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Table 5 – Predictive factors of cancer in multivariable analysis. 
 
Factor OR P value 
Age 5.39 
CI 95%: 2.08 – 13.9 
< 0.001 
Family history of cancer 1.73 
CI 95%: 1.03 – 2.92 
0.04 
Disease duration 1.27 
CI 95%: 0.97 – 1.64 
0.08 
Pituitary radiotherapy 1.76 
CI 95%: 0.89 – 3.45 
0.10 
Diabetes 1.39 
CI 95%: 0.76 – 2.57 
0.28 
Gender 1.19 
CI 95%: 0.69 – 2.05 
0.51 
IGF-I at last visit 1.03 
CI 95%: 0.76 – 1.38 
0.87 
 
OR=Odds Ratio, CI=Confidence Interval 
For continuous variables, OR are reported for an interquartile range increase, i.e. 19 years of difference for 
age and 1.5 SDS for IGF-I 
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Figure 1   
 
 
Black bars indicate studies showing a positive association between acromegaly and cancer, striped bars negative 
studies, and white bars studies that do not conclude whether an association is either present or not. Studies focusing on 
mortality only are marked by the letter M. 
References for the studies are as follows: 1= (Mustacchi & Shimkin 1957), 2= (Wright et al. 1970), 3= (Alexander et al. 
1980), 4 =  (Bengtsson et al. 1988), 5= (Nabarro 1987), 6= (Pines et al 1985), 7= (Barzilay et al 1991), 8= (Ron et al 
1991), 9= (Rajasoorya et al 1994), 10= (Cheung & Boyages 1997 ), 11= (Orme et al 1998), 12= (Popovic et al 1998), 
13= (Higuchi et al 2000), 14= (Baris et al 2002), 15= (Holdaway et al 2004), 16= (Ayuk et al 2004), 17= (Kurimoto et 
al 2008), 18= (Gullu et al 2010), 19= (Bałdys-Waligórska et al 2010), 20= (Kauppinen-Makelin et al 2010), 21= 
(Arosio et al 2012), 22= (Dagdelen et al 2014), 23= (Mercado et al 2014), 24= (Petroff et al 2015), 25= (Cheng et al 
2015),  26= (Dal et al 2016), 27= (Maione et al. 2017) 
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